BigenCell Presents Preclinical Poster on Blood and Solid Tumor-Targeted CAR-T at American Association for Cancer Research

VigenCell, a company specializing in immune cell therapies, announced on the 21st that it presented a poster at the American Association for Cancer Research (AACR) showcasing the in vitro and animal experimental antitumor efficacy results of chimeric antigen receptor (CAR)-T cells using a novel CD30-derived co-stimulatory signaling domain.

Executive Director Jo Hyun-il (third from the left) of VigenCell is explaining research results to visitors at the American Association for Cancer Research (AACR).
[Photo by VigenCell]

The AACR, one of the world's top three cancer research societies, was held in Orlando, Florida, USA, from the 14th to the 19th (local time).

VigenCell’s poster presentation detailed research demonstrating that CAR-T cells targeting hematologic and solid tumors using the CD30-derived co-stimulatory signaling domain showed superior antitumor efficacy in both in vitro and animal experiments compared to conventional CAR signaling domains.

In in vitro experiments targeting CD19-expressing hematologic cancers, second- and third-generation CAR-T cells containing the CD30-derived co-stimulatory domain exhibited similar results to the control group in terms of CAR expression levels, cytotoxicity, and cytokine secretion, according to VigenCell. In animal experiments, CAR-T cells including CD30 suppressed tumor growth compared to the control group, resulting in extended survival periods and less weight loss in mice.

Furthermore, repeated experiments using CAR-T cells produced from different donors yielded consistent results, confirming the superiority of the CD30-derived co-stimulatory domain across various donors. CAR-T cells containing the CD30 co-stimulatory domain targeting epithelial cell adhesion molecule (EpCAM) for solid tumors demonstrated superior antitumor efficacy compared to controls in both in vitro and animal experiments.

The company explained that these findings are significant as the CD30-derived co-stimulatory signaling domain could serve as a new platform for developing immune cell therapies based on CAR targeting hematologic or solid tumors.

Hyunil Cho, General Manager (Executive Director) of VigenCell’s ViRanger group, stated, "It is meaningful that the CD30-derived co-stimulatory signaling domain has demonstrated excellent efficacy and applicability against both hematologic and solid tumors. We will strive to advance the development of CAR-T cell therapies targeting solid tumors and the VR-CAR pipeline using universal allogeneic CAR-gamma delta T cells to promote the development of superior therapeutics and technology transfer."

This content was produced with the assistance of AI translation services.